Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Chronic Lymphocytic Leukemia (CLL) Pipeline Review, H2 2012
Publication Date Sep 2012
Publisher Global Markets Direct
Product Type Report
Pages 209
Single User License $ 2500.00
Site User License $ 5000.00
Corporate User License $ 7500.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

Chronic Lymphocytic Leukemia (CLL) Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL). Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chronic Lymphocytic Leukemia (CLL).
- A review of the Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Chronic Lymphocytic Leukemia (CLL) Overview 13
Therapeutics Development 14
An Overview of Pipeline Products for Chronic Lymphocytic Leukemia (CLL) 14
Chronic Lymphocytic Leukemia (CLL) Therapeutics under Development by Companies 16
Chronic Lymphocytic Leukemia (CLL) Therapeutics under Investigation by Universities/Institutes 22
Late Stage Products 29
Comparative Analysis 29
Mid Clinical Stage Products 30
Comparative Analysis 30
Early Clinical Stage Products 31
Comparative Analysis 31
Discovery and Pre-Clinical Stage Products 32
Comparative Analysis 32
Chronic Lymphocytic Leukemia (CLL) Therapeutics Products under Development by Companies 33
Chronic Lymphocytic Leukemia (CLL) Therapeutics Products under Investigation by Universities/Institutes 36
Companies Involved in Chronic Lymphocytic Leukemia (CLL) Therapeutics Development 50
Bristol-Myers Squibb Company 50
Genzyme Corporation 51
Boehringer Ingelheim GmbH 52
F. Hoffmann-La Roche Ltd. 53
Kyowa Hakko Kirin Co., Ltd. 54
Abbott Laboratories 55
Amgen Inc. 56
Sanofi-Aventis 57
GlaxoSmithKline plc 58
Genentech, Inc. 59
MedImmune LLC 60
Gilead Sciences, Inc. 61
Merck & Co., Inc. 62
Emergent BioSolutions Inc. 63
Lentigen Corporation 64
Celltrion, Inc. 65
BioMarin Pharmaceutical Inc. 66
Gedeon Richter Plc. 67
ImmunoGen, Inc. 68
Nippon Shinyaku Co., Ltd. 69
Genmab A/S 70
Santaris Pharma A/S 71
Cyclacel Pharmaceuticals Inc. 72
Celgene Corporation 73
Incyte Corporation 74
4SC AG 75
Celldex Therapeutics, Inc. 76
AEterna Zentaris Inc. 77
IMMUNOMEDICS, INC 78
MethylGene Inc 79
Portola Pharmaceuticals, Inc. 80
Mundipharma International Limited 81
Pharmacyclics, Inc. 82
MorphoSys AG 83
Threshold Pharmaceuticals, Inc. 84
Hybrigenics S.A. 85
Oryzon 86
Spectrum Pharmaceuticals, Inc. 87
Memgen, LLC. 88
Curacyte AG 89
Ascenta Therapeutics, Inc. 90
Arno Therapeutics, Inc. 91
Semafore Pharmaceuticals, Inc. 92
NOXXON Pharma AG 93
Fate Therapeutics, Inc. 94
SBI Biotech Co., Ltd. 95
Tragara Pharmaceuticals, Inc. 96
Cylene Pharmaceuticals, Inc. 97
Biothera 98
Nereus Pharmaceuticals, Inc. 99
Astellas Pharma GmbH 100
Cancer Therapeutics CRC Pty Ltd 101
LFB Biotechnologies, S.A.S.U. 102
KAEL-GemVax 103
Laboratoire français de Fractionnement et de Biotechnologies 104
Advancell 105
Chronic Lymphocytic Leukemia (CLL) Therapeutics Assessment 106
Assessment by Monotherapy Products 106
Assessment by Combination Products 107
Assessment by Route of Administration 108
Assessment by Molecule Type 110
Drug Profiles 112
obinutuzumab - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
ibrutinib - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
bendamustine hydrochloride - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
GS-1101 - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Campath + Fludara - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
dinaciclib - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
Prograf + Methotrexate - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
Fludarabine + Cyclophosphamide + Rituximab - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Fludarabine + Cyclophosphamide + Campath - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
Ofatumumab + Bendamustine - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
Ofatumumab + Chlorambucil - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
Fludara + Cytoxan + Rituxan - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Nipent + Cytoxan + Rituxan - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
GS 1101 + Bendamustine + Rituximab - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
GS-1101 + Rituximab - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
lenalidomide - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
Arzerra + Fludarabine + Cyclophosphamide - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
Ofatumumab + Chlorambucil - Drug Profile 140
Product Description 140
Mechanism of Action 140
R&D Progress 140
RG7159 + Chlorambucil - Drug Profile 142
Product Description 142
Mechanism of Action 142
R&D Progress 142
Fludarabine + Total Body Irradiation + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 143
Product Description 143
Mechanism of Action 143
R&D Progress 143
Fludarabine + Rituximab - Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 145
Rituximab + Fludarabine + Cyclophosphamide - Drug Profile 147
Product Description 147
Mechanism of Action 147
R&D Progress 147
ofatumumab - Drug Profile 149
Product Description 149
Mechanism of Action 149
R&D Progress 149
ofatumumab - Drug Profile 153
Product Description 153
Mechanism of Action 153
R&D Progress 153
rituximab - Drug Profile 157
Product Description 157
Mechanism of Action 157
R&D Progress 157
Bendamustine + Rituximab - Drug Profile 158
Product Description 158
Mechanism of Action 158
R&D Progress 158
prednimustine - Drug Profile 160
Product Description 160
Mechanism of Action 160
R&D Progress 160
fludarabine phosphate - Drug Profile 161
Product Description 161
Mechanism of Action 161
R&D Progress 161
Fludarabine + Cyclophosphamide - Drug Profile 162
Product Description 162
Mechanism of Action 162
R&D Progress 162
Fludarabine + Cyclophosphamide + Rituximab + Lenalidomide - Drug Profile 163
Product Description 163
Mechanism of Action 163
R&D Progress 164
epoetin alfa - Drug Profile 165
Product Description 165
Mechanism of Action 165
R&D Progress 165
Rituximab + Cyclophosphamide + Fludarabine - Drug Profile 166
Product Description 166
Mechanism of Action 166
R&D Progress 166
Rituximab + Fludarabine Phosphate - Drug Profile 168
Product Description 168
Mechanism of Action 168
R&D Progress 168
Allogeneic Stem Cell Transplantation - Drug Profile 169
Product Description 169
Mechanism of Action 169
R&D Progress 169
Chronic Lymphocytic Leukemia (CLL) Therapeutics Drug Profile Updates 170
Chronic Lymphocytic Leukemia (CLL) Therapeutics Discontinued Products 184
Chronic Lymphocytic Leukemia (CLL) Therapeutics - Dormant Products 188
Chronic Lymphocytic Leukemia (CLL) Product Development Milestones 201
Featured News & Press Releases 201
Aug 24, 2012: TG Therapeutics Announces Poster Presentation For Ublituximab At 7th International Workshop On Waldenstrom's Macroglobulinemia 201
Aug 01, 2012: Pharmacyclics To Receive $50m Milestone Payment From Janssen Biotech 201
Jul 11, 2012: Noxxon Initiates Phase IIa Study Of Anti-CXCL12/SDF-1 Spiegelmer NOX-A12 For Treatment Of Chronic Lymphocytic Leukemia 202
Jun 16, 2012: Pharmacyclics Announces Updated Results For Ibrutinib At European Hematology Association Annual Congress 202
Jun 16, 2012: Pharmacyclics Announces Updated Results For Ibrutinib Combination Study At European Hematology Association Annual Congress 203
Jun 04, 2012: Pharmacyclics Presents Updated Results From Phase Ib/II CLL/SLL Trial Of Ibrutinib At ASCO 2012 Annual Meeting 204
Jun 04, 2012: Pharmacyclics Presents Updated Safety And Efficacy Data From Phase Ib/II CLL/SLL Combination Trial Of PCI-32765 With Bendamustine And Rituximab At ASCO Annual Meeting 205
Jun 04, 2012: Threshold Highlights Phase I Results Of TH-302 At ASCO Annual Meeting 205
May 31, 2012: Tragara Describes Mechanism Of Action Of Anti-Tumor Drug TG02 206
May 24, 2012: Genmab Receives DKK20m Milestone Payment From GSK 207
Appendix 208
Methodology 208
Coverage 208
Secondary Research 208
Primary Research 208
Expert Panel Validation 208
Contact Us 209
Disclaimer 209

List of Tables
List of Tables
Number of Products Under Development for Chronic Lymphocytic Leukemia (CLL), H2 2012 14
Products under Development for Chronic Lymphocytic Leukemia (CLL) Comparative Analysis, H2 2012 15
Number of Products under Development by Companies, H2 2012 17
Number of Products under Development by Companies, H2 2012 (Contd..1) 18
Number of Products under Development by Companies, H2 2012 (Contd..2) 19
Number of Products under Development by Companies, H2 2012 (Contd..3) 20
Number of Products under Development by Companies, H2 2012 (Contd..4) 21
Number of Products under Investigation by Universities/Institutes, H2 2012 23
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 24
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 25
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 26
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 28
Comparative Analysis by Late Stage Development, H2 2012 29
Comparative Analysis by Mid Clinical Stage Development, H2 2012 30
Comparative Analysis by Early Clinical Stage Development, H2 2012 31
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 32
Products under Development by Companies, H2 2012 33
Products under Investigation by Universities/Institutes, H2 2012 36
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 37
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 38
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 39
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 40
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 41
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 42
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 43
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 44
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 45
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 46
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 47
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 48
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 49
Bristol-Myers Squibb Company, H2 2012 50
Genzyme Corporation, H2 2012 51
Boehringer Ingelheim GmbH, H2 2012 52
F. Hoffmann-La Roche Ltd., H2 2012 53
Kyowa Hakko Kirin Co., Ltd., H2 2012 54
Abbott Laboratories, H2 2012 55
Amgen Inc., H2 2012 56
Sanofi-Aventis, H2 2012 57
GlaxoSmithKline plc, H2 2012 58
Genentech, Inc., H2 2012 59
MedImmune LLC, H2 2012 60
Gilead Sciences, Inc., H2 2012 61
Merck & Co., Inc., H2 2012 62
Emergent BioSolutions Inc., H2 2012 63
Lentigen Corporation, H2 2012 64
Celltrion, Inc., H2 2012 65
BioMarin Pharmaceutical Inc., H2 2012 66
Gedeon Richter Plc., H2 2012 67
ImmunoGen, Inc., H2 2012 68
Nippon Shinyaku Co., Ltd., H2 2012 69
Genmab A/S, H2 2012 70
Santaris Pharma A/S, H2 2012 71
Cyclacel Pharmaceuticals Inc., H2 2012 72
Celgene Corporation, H2 2012 73
Incyte Corporation, H2 2012 74
4SC AG, H2 2012 75
Celldex Therapeutics, Inc., H2 2012 76
AEterna Zentaris Inc., H2 2012 77
IMMUNOMEDICS, INC, H2 2012 78
MethylGene Inc, H2 2012 79
Portola Pharmaceuticals, Inc., H2 2012 80
Mundipharma International Limited, H2 2012 81
Pharmacyclics, Inc., H2 2012 82
MorphoSys AG, H2 2012 83
Threshold Pharmaceuticals, Inc., H2 2012 84
Hybrigenics S.A., H2 2012 85
Oryzon, H2 2012 86
Spectrum Pharmaceuticals, Inc., H2 2012 87
Memgen, LLC., H2 2012 88
Curacyte AG, H2 2012 89
Ascenta Therapeutics, Inc., H2 2012 90
Arno Therapeutics, Inc., H2 2012 91
Semafore Pharmaceuticals, Inc., H2 2012 92
NOXXON Pharma AG, H2 2012 93
Fate Therapeutics, Inc., H2 2012 94
SBI Biotech Co., Ltd., H2 2012 95
Tragara Pharmaceuticals, Inc., H2 2012 96
Cylene Pharmaceuticals, Inc., H2 2012 97
Biothera, H2 2012 98
Nereus Pharmaceuticals, Inc., H2 2012 99
Astellas Pharma GmbH, H2 2012 100
Cancer Therapeutics CRC Pty Ltd, H2 2012 101
LFB Biotechnologies, S.A.S.U., H2 2012 102
KAEL-GemVax, H2 2012 103
Laboratoire français de Fractionnement et de Biotechnologies, H2 2012 104
Advancell, H2 2012 105
Assessment by Monotherapy Products, H2 2012 106
Assessment by Combination Products, H2 2012 107
Assessment by Stage and Route of Administration, H2 2012 109
Assessment by Stage and Molecule Type, H2 2012 111
Chronic Lymphocytic Leukemia (CLL) Therapeutics Drug Profile Updates 170
Chronic Lymphocytic Leukemia (CLL) Therapeutics Discontinued Products 184
Chronic Lymphocytic Leukemia (CLL) Therapeutics Discontinued Products (Contd..1) 185
Chronic Lymphocytic Leukemia (CLL) Therapeutics Discontinued Products (Contd..2) 186
Chronic Lymphocytic Leukemia (CLL) Therapeutics Discontinued Products (Contd..3) 187
Chronic Lymphocytic Leukemia (CLL) Therapeutics Dormant Products 188
Chronic Lymphocytic Leukemia (CLL) Therapeutics Dormant Products (Contd..1) 189
Chronic Lymphocytic Leukemia (CLL) Therapeutics Dormant Products (Contd..2) 190
Chronic Lymphocytic Leukemia (CLL) Therapeutics Dormant Products (Contd..3) 191
Chronic Lymphocytic Leukemia (CLL) Therapeutics Dormant Products (Contd..4) 192
Chronic Lymphocytic Leukemia (CLL) Therapeutics Dormant Products (Contd..5) 193
Chronic Lymphocytic Leukemia (CLL) Therapeutics Dormant Products (Contd..6) 194
Chronic Lymphocytic Leukemia (CLL) Therapeutics Dormant Products (Contd..7) 195
Chronic Lymphocytic Leukemia (CLL) Therapeutics Dormant Products (Contd..8) 196
Chronic Lymphocytic Leukemia (CLL) Therapeutics Dormant Products (Contd..9) 197
Chronic Lymphocytic Leukemia (CLL) Therapeutics Dormant Products (Contd..10) 198
Chronic Lymphocytic Leukemia (CLL) Therapeutics Dormant Products (Contd..11) 199
Chronic Lymphocytic Leukemia (CLL) Therapeutics Dormant Products (Contd..12) 200

List of Figures
List of Figures
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2012 14
Products under Development for Chronic Lymphocytic Leukemia (CLL) Comparative Analysis, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 22
Late Stage Products, H2 2012 29
Mid Clinical Stage Products, H2 2012 30
Early Clinical Stage Products, H2 2012 31
Discovery and Pre-Clinical Stage Products, H2 2012 32
Assessment by Monotherapy Products, H2 2012 106
Assessment by Combination Products, H2 2012 107
Assessment by Route of Administration, H2 2012 108
Assessment by Stage and Route of Administration, H2 2012 109
Assessment by Molecule Type, H2 2012 110
Assessment by Stage and Molecule Type, H2 2012 111

Title Date Price
By Netscribes (India) Pvt. Ltd.
May 2012 $0.00
Medical Devices Market in Russia 2009-2013
By Infiniti Research Ltd
Medical devices comprise surgical equipment & appliances, diagnostic devices, X-ray, ophthalmic equipment, laboratory devices & diagnostics, dental equipment, medical disposables and others.The Russia ...Read More
Mar 2010 $1500.00
2010 Perfect Vision GmbH - Medical Equipment - Deals and Alliances Profile
By GlobalData
2010 Perfect Vision GmbH - Medical Equipment - Deals and Alliances ProfileSummary20/10 Perfect Vision AG is engaged in the development, manufacturing and marketing of innovative technologies for raisi ...Read More
Jan 2012 $250.00
2010 U.S. Ambulatory Surgical & Emergency Centers Industry Report
By Barnes Reports
The U.S Ambulatory Surgical & Emergency Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features ...Read More
Jan 2010 $149.00
2010 U.S. Biological Product Manufacturing Industry Report
By Barnes Reports
The U.S. Biological Product Manufacturing Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 ...Read More
Jan 2010 $149.00
2010 U.S. HMO Medical Centers Industry Report
By Barnes Reports
The U.S HMO Medical Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and 20 ...Read More
Jan 2010 $149.00
2010 U.S. Home Health Care Services Industry Report
By Barnes Reports
The Home Health Care Services Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and ...Read More
Oct 2009 $149.00
2010 U.S. Kidney Dialysis Centers Industry Report
By Barnes Reports
The U.S Kidney Dialysis Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current an ...Read More
Jan 2010 $149.00
2010 U.S. Medical & Surgical Hospitals Industry Report
By Barnes Reports
The Medical & Surgical Hospitals Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current a ...Read More
Oct 2009 $149.00
2010 U.S. Medical Laboratories Industry Report
By Barnes Reports
The Medical Laboratories Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and 2011 ...Read More
Oct 2009 $149.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9425069161
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z